Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women

References

• Warren MP, Halpert S. Hormone replacement therapy controversies, pros and cons. Best Pract Res 2004;18:317–332
   Web of Science ®Google Scholar
• Somukiran A, Erel CT, Demirci F, Senturk ML. The effect of tibolone versus 17β-estradiol on climacteric symptoms in women with surgical menopause: a randomized, cross-over study. Maturitas 2007;56:61–68
   PubMed Web of Science ®Google Scholar
• Bjorn I, Backstrom T, Lalos A, Sundstrom-Poromaa I. Adverse mood effects during postmenopausal hormone treatment in relation to personality traits. Climacteric 2006;9:290–297
   PubMed Web of Science ®Google Scholar
• Bruhat M, Rudolf K, Vaheri R, Kainulainen P, Timonen V, Viitanen A. Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy. Maturitas 2001;40:259–271
   PubMed Web of Science ®Google Scholar
• Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065–1079
   PubMed Web of Science ®Google Scholar
• Larson B, Collins A, Landgren BM. Urogenital and vasomotor symptoms in relation to menopausal status and the use of hormone replacement therapy (HRT) in healthy women during transition to menopause. Maturitas 1997;28:99–105
   PubMed Web of Science ®Google Scholar
• Timmer CJ, Verheul HAM, Doorstam DP. Pharmacokinetics of tibolone in early and late postmenopausal women. Br J Clin Pharmacol 2002;54:101–106
   PubMed Web of Science ®Google Scholar
• Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 2001;87:116–123
   Google Scholar
• Greene JG. Constructing a standard climacteric scale. Maturitas 1998;29:25–31
   PubMed Web of Science ®Google Scholar
• Rosen R, Brown C, Heiman J, et al The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191–208
   PubMed Web of Science ®Google Scholar
• Derman RJ, Dawood MY, Stone S. Quality of life during sequential hormone replacement therapy: a placebo controlled study. Int J Fertil 1995;40:73–78
   Google Scholar
• Ulrich LG, Barlow DH, Sturdee DW, et al Quality of life and patient preference for sequential versus continuous combined HRT: the UK Kliofem multicenter study experience. Int J Gynecol Obstet 1997;59:11–17
   PubMedGoogle Scholar
• Barentsen R, Van de Waijer PHM, Van Gend S, Foekema H. Climacteric symptoms in a representative Dutch population sample as measured with the Greene Climacteric Scale. Maturitas 2001;38:123–128
   PubMed Web of Science ®Google Scholar
• Lam PM, Cheung GWY, Shek DTL, Lee DTS, Haines CJ, Chung TKH. A randomized placebo-controlled, crossover study of tibolone (Livial) on menopause symptoms, psychological well-being, and dyadic relationship of postmenopausal Chinese women and their spouses. Menopause 2004;11:416–422
   PubMed Web of Science ®Google Scholar
• Liu JH. Therapeutic effects of progestins, androgens, and tibolone for menopausal symptoms. Am J Med 2005;118:88–92
   PubMedGoogle Scholar
• Hammar M, Christau S, Nathorst-Boos J, Rud T, Garre K. A double-blind, randomized trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. BJOG 1998;105:904–911
   Web of Science ®Google Scholar
• Huber J, Palacios S, Berglund L, et al Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. BJOG 2002;109:886–893
   PubMed Web of Science ®Google Scholar
• Mathur RS, Landgreve SC, Moody LO, Semmens JP, Williamson HO. The effect of estrogen treatment on plasma concentrations of steroid hormones, gonadotropins, prolactin and sex hormone binding globulin in postmenopausal women. Maturitas 1985;7:129–133
   PubMed Web of Science ®Google Scholar
• Cayan F, Dilek U, Pata O, Dilek S. Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women. J Sex Med 2008;5:132–138
   PubMed Web of Science ®Google Scholar
• Nijland EA, Weijmar Schultz WCM, Nathorst-Boos J, et al Tibolone and transdermal E2/NETA for the treatment of female sexual function in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med 2008;5:646–656
   PubMed Web of Science ®Google Scholar
• Osmanagaoglu MA, Atasaral T, Baltaci O, Bozkaya H. Effect of different preparations of hormone therapy on sexual dysfunction in naturally postmenopausal women. Climacteric 2006;9:464–472
   PubMed Web of Science ®Google Scholar
• Kokcu A, Cetinkaya MB, Yanik F, Alper T, Malatyalioglu E. The comparison of effects of tibolone and conjugated estrogen medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. Maturitas 2000;36:75–80
   PubMed Web of Science ®Google Scholar
• Egarter C, Topcuoglu A, Vogl S, Sator M. Hormone replacement therapy with tibolone: effects on sexual functioning in postmenopausal women. Acta Obstet Gynecol Scand 2002;81:649–653
   PubMed Web of Science ®Google Scholar
• Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol 2001;76:231–238
   PubMed Web of Science ®Google Scholar
• Palacios S, Tobar AC, Menendez C. Sexuality in the climacteric years. Maturitas 2002;43:S69–S77
   PubMed Web of Science ®Google Scholar